Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of a recombinant 9-valent HPV vaccine in Chinese men aged 18-45 years
CTR20223306Phase 3Active
- Sponsor
- Beijing Health Guard
- Start
- Dec 2022
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of human papillomavirus 9-valent vaccine, recombinant in human papillomavirus infection, anogenital warts, anal intraepithelial neoplasia (AIN), anal cancer, penile intraepithelial neoplasia (PeIN), sponsored by Beijing Health Guard. Started Dec 2022; status: active.
02
Drugs
human papillomavirus 9-valent vaccine, recombinant
03
Conditions
human papillomavirus infectionanogenital wartsanal intraepithelial neoplasia (AIN)anal cancerpenile intraepithelial neoplasia (PeIN)
Beyond the preview
Go deeper on CTR20223306.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20223306.